Skip to content

Ayurveda medicines role in Treatment of COVID-19

A clinical Study to evaluate the effect of Ayurveda medicines in the management of COVID-19

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032755
Enrollment
200
Registered
2021-04-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Kabasura kudineer: Kabasura kudineer 2 tablets taken thrice a day before food Control Intervention1: Standard control group: only ongoing allopathic medicines Total duration of the the

Sponsors

Sree Ramachandra Health services Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Confirmed case of COVID-19 infection by laboratory tests and suffering from clinical signs and symptoms fever, cough, sore throat, nasal congestion, malaise and headache associated with or without difficulty in breathing 2. Age limit â?? 20 to 60 years, both Male & Female 3. Patients whom ventilator support is not required 4. Patients willing to give their consent to participate in the clinical trial

Exclusion criteria

Exclusion criteria: 1. COVID-19 positive patients above 60 years of age & below 20 years 2. Patients with acute renal failure or Stage 4 CKD or Liver Failure (AST/ALT >5 times elevated) 3. Patients on Immuno-suppression therapy 4. Pregnant Women or lactating mothers

Design outcomes

Primary

MeasureTime frame
1. Proportion of Out-Patients not hospitalised 2. Early recovery in the signs and symptoms of COVID-19 by adding Ayurvedic medicines which are effective in fever, symptoms of respiratory tract and by enhancing immunity of body by adding Rasayana drugs Timepoint: Baseline , 4 th day , 7 th day, 14 th day

Secondary

MeasureTime frame
1.Improvement of quality life of cases. 2.Time to recovery through 1month. 3.Clinical status-2 point improvement on ordinal scale for Covid -19. 4.Progression to severe disease. Timepoint: Day, 7 and Day 14

Countries

India

Contacts

Public ContactDrMRavi Kumar Reddy

Sree Ramachandra Health Services Pvt Ltd

ramheart@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026